Trial Profile
Effect of teriflunomide in patients with relapsing forms of multiple sclerosis who were previously receiving natalizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2018
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 30 Oct 2018 Status changed from recruiting to completed, according to the Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 16 Jun 2015 New trial record